v3.26.1
Significant Agreements - Novo Nordisk Share Purchase Agreement (Details) - Novo Nordisk - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2026
Dec. 31, 2025
Jul. 08, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Share Purchase Agreement, Upfront Payment       $ 60,000,000.0
Share Purchase Agreement, Potential Payment Upon Achievement of Development and Sales Milestones   $ 1,080,000,000.00    
Revenue from License and Intellectual Property, Share Purchase Agreement $ 0 (50,000,000.0)    
Milestone achievement, Clinical milestone   50,000,000.0    
Accounts Receivable, after Allowance for Credit Loss   $ 0 $ 0